AZN AstraZeneca Plc: תחזית צמיחת רווח נקי למניה לשנה הבאה
AstraZeneca PLC (AZN) maintains its resilience through new targeted therapies and the expansion of its oncology portfolio. The historical trend of n+1 profit forecasts confirms this potential, where 10.60 represents the latest level value. High margins are based on rare disease patents that create a momentum effect. Revenues rely on global procurement of high-cost prescription drugs by state healthcare systems and clinics.
AZN (astrazeneca.com): פילוחים אנליטיים ודוחות לפי אינדיקטורים
AstraZeneca PLC (AZN) maintains a dominant position in the treatment of oncology and cardiovascular pathologies thanks to a strong portfolio of innovations. This metric measures the expected growth rate of earnings per share, reflecting the analysts' consensus forecast for future returns. By analyzing the valuation of future earnings per share dynamics, an investor can identify rising uncertainty through the amplitude of the indicator's fluctuations. A stable trend confirms the resilience of the business model across both B2B and B2C segments.
